Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

skip to main content

Japanese cedar (JC) pollen sublingual immunotherapy (SLIT) tablets show sustained disease-modifying effects

Published: July 29, 2021

Allergen immunotherapy is considered to be the only treatment that results in long-term remission of allergic symptoms and suppression of sensitization to novel allergens through a disease-modifying effect. JC pollen sublingual immunotherapy (SLIT) tablets provided sustained efficacy in a treatment duration-dependent manner. However, the magnitude and duration of disease modification after treatment cessation has not been evaluated.   

In a randomized, parallel-group, placebo-controlled, double-blind trial conducted with 1042 patients (age, 5–64 years) with JC pollinosis in The Journal of Allergy and Clinical Immunology: in Practice, Yonekura and colleagues assessed the disease-modifying effects of JC pollen SLIT tablets over 5 years (2015–2019), which comprised a 3-year treatment period and 2-year follow-up.

JC pollen SLIT tablets reduced the Total Nasal Symptom and Medication Score significantly in a treatment duration-dependent manner. However, the greatest relative reduction was in the group administered for 3 years both during the treatment period (third season, 46.3% vs. placebo, P < 0.001) and during the 2-year follow-up period (fourth and fifth seasons, 45.3% and 34.0% vs. placebo, respectively, P < 0.001). These additional data from this 5-year study demonstrated that administration of JC pollen SLIT tablets for ~18 months also provided long-term benefits after treatment cessation, but that 3 years of treatment provided more robust disease-modifying effects.

The Journal of Allergy and Clinical Immunology: In Practice is an official journal of the AAAAI, focusing on practical information for the practicing clinician.

Full Article